|
KMID : 0360319890210010067
|
|
Journal of Korean Cancer Research Association
1989 Volume.21 No. 1 p.67 ~ p.73
|
|
|
Effect of Cisplatin on Glomerular Filtration Rate and Effective Renal Plasma Flow
|
|
김용현/Kim, Yong-Hyun
홍원선/임상무/송재관/김영환/홍성운/이진오/Hong, Weon-Seon/Lim, Sang-Moo/Song, Jae-Kwan/Kim, Young-Whan/Hong, Seong-Woon/Lee, Jhin-Oh
|
|
|
Abstract
|
|
|
|
While cisplatin has been widely used in the treatment of a variety of cancers, nephrotoxicity is one of the major problems which frequently limit clinical usefulness of cisplatin. This study has been conducted to investigate nephrotoxicity of cisplatin in terms of changes in glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) measured by the simultaneous use of ^(99m)Tc-DTPA and ^(131)I-0IH, before and after administration of cisplatin, in 12 patients with lung cancer and four patients with esophageal cancer. Cisplatin was administrated at total doses of 75-100 mg/㎡ with two hour hydration and diuresis method. GFR determined by the use of ^(99m)Tc-DTPA had a good correlation with 24-hour creatinine clearance rate (r=0.60, p<0.001). GFR and filtration fraction decreased immediately after administration of cisplatin, however, they showed a tendency to be recovered four weeks after administration. ERPF was not changed between before, immediately after and four weeks after administration of cisplatin. GFRs before and immediately after administration of cisplatin were analyzed with regard to age, sex, performance status, previous adminstration of cisplatin and method of administration, demonstrating none of these factors had any influence on the rate of decrease in GFR except method of administration. Administration of cisplatin as a single dose lowered GFR more compared with that as divided doses. In this study, we have also demonstrated that the simuitaneous use of ^(99m)Tc-DTPA and ^(131)I-0IH was a useful tool for the measurement of GFR and ERPF, respectively.
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
 
|
|